A b s t r a c t

We report changes in cardiac troponin-T (TnT) and a new plasma stroke biomarker panel (D dimer, Bnatriuretic peptide [BNP], matrix metalloproteinase-9 [MMP-9], S-100 β, Biosite Diagnostics, San Diego, CA) in 30 nonprofessional marathon runners before and immediately after the 2005 Boston Marathon. Following competition, there was a statistically significant increase in MMP-9 (P < .001) and D dimer (P < .001). Nonsignificant changes in S-100 β and BNP were observed. Premarathon and postmarathon values for a multimarker stroke index increased from 0.97 (normal) to 3.5 (low risk or more; P < .001). Two subjects had index values more than the high-risk cutoff value. Mean TnT premarathon and postmarathon levels increased (from <0.01 to 0.03 ng/mL; P < .0001). After the marathon, with a cutoff value of 0.05 ng/mL, 7 runners (23%) had values above the manufacturer's recommended cutoff for myocardial damage. Although biochemical evidence of myocardial damage following strenuous exercise may reflect myocardial stunning or subclinical ischemia, the changes in the stroke index and values for individual stroke markers may reflect a systemic inflammatory response to exertional rhabdomyolysis which is common, but the possibility of subclinical central nervous system damage cannot be excluded.
Marathon runners are well known to exhibit a number of abnormalities in laboratory tests following competition, including markers reflecting rhabdomyolysis and myocardial ischemia, creatine kinase (CK), its isoenzyme CK-MB, and troponins I and T; left ventricular function, B-type natriuretic peptides (BNP and NT-proBNP); and D dimer, C-reactive protein (CRP), and other hemostatic/inflammatory markers. [1] [2] [3] [4] Although the significance of some of these biochemical changes is not clear, it has been postulated that elevations in cardiac-specific troponins may reflect reversible myocardial stunning or, in some cases, minor myocardial damage indicating true ischemic injury and cell death. 3, 5 Biochemical evidence for thromboembolic, ischemic, or other injury to noncardiac organs in otherwise healthy athletes is sparse. For example, cerebral edema secondary to exercise-associated hyponatremia has been reported but is uncommon. 6 A number of biomarkers in plasma have been identified and studied for the evaluation of stroke, including matrix metalloproteinase-9 (MMP-9), S-100 β, neuron-specific enolase, B-type natriuretic peptide (BNP), D dimer, monocyte chemotactic factor, von Willebrand factor, and other markers. 7, 8 Recently, Biosite Diagnostics (San Diego, CA) developed a rapid immunoassay multimarker stroke panel, which purports to be useful for the detection of stroke in symptomatic patients. The Triage stroke panel will be available in Europe in 2006 and consists of S-100 β, MMP-9, BNP, and D dimer. The 4 markers are interpreted by a proprietary software algorithm (MultiMarker Index, Biosite Diagnostics) whereupon the instrument software analyzes information from the 4 biomarkers to yield a "stroke index" ranging from 0 to 10 with 2 cutoffs of 1.3 or less (low risk) and 5.9 or more (high risk) for stroke. The new stroke panel test is being reviewed by the US Food and Drug Administration.
We previously examined the behavior of analytes for cardiac injury and wall stress in nonelite marathon runners. The purpose of the present study was to again examine the behavior of markers of cardiovascular injury and stress (troponin and BNP) while also examining the results of the new stroke panel among nonelite runners completing the 2005 Boston Marathon.
Materials and Methods
We recruited 35 marathon runners (mean ± SD age, 49 ± 7 years; 29 men, 6 women) scheduled to run the 109th Boston Athletic Association Marathon in 2005 by open invitation to local running clubs. These runners had an approximate mean training mileage of 42 ± 9 miles per week and an approximate mean finishing time of 4 hours. It is not known to what extent these subjects were representative of the overall population of the race. We excluded subjects with a history of cardiovascular disease. The athletes volunteered for the study and provided written consent. Comprehensive screening consisted of a general health questionnaire to ascertain personal, family, and marathon history and the use of prescription medications. Participants were screened not more than 1 week before and immediately following (<15 minutes) the marathon. Whole blood samples were obtained before and immediately following the race into EDTA tubes and serum separator tubes and processed immediately. Of the 35 subjects, only 30 provided paired before and after race samples for analysis. None of the specimens demonstrated signs of hemolysis. Aliquots of the samples were frozen within 1 hour of collection at -80°C.
The 2005 Boston Marathon was run at a temperature of 69°F to 70°F with light north/northwesterly winds at 3 mph; 18,322 runners began the race, and 17,528 completed it for a completion percent of 95.7%. The mean finishing time for the runners in our study was 250 ± 33 minutes. None of the subjects experienced adverse events necessitating medical treatment before or after the race; specifically, none of the runners collapsed or demonstrated any signs of cardiac or cerebral insufficiency, and they were deemed in medically stable condition following the race. The protocol was approved by the institutional review boards of McLean Hospital, Belmont, MA, and Partners Healthcare System/Massachusetts General Hospital, Boston.
Plasma samples were tested immediately for cardiac troponin T (TnT) using a Roche Elecsys 2010 immunoassay analyzer (Roche Diagnostics, Indianapolis, IN). The Biosite Triage stroke panel was performed on EDTA-anticoagulated plasma samples at Biosite Diagnostics, and the stroke index was calculated by the software (MultiMarker Index) included with the assay on the instrument. Serum sodium levels were measured on a Hitachi 917 autoanalyzer (Roche Diagnostics).
A 2-tailed paired Student t test was used to assess premarathon and postmarathon changes. Statistical analysis was performed using the Analyze-It (Analyze-It Software, Leeds, England) for Microsoft Excel software (Microsoft, Redmond, WA). The precision of each of the 4 component biomarkers of the stroke panel are as follows: BNP, 16%; D dimer, 11%; MMP-9, 10%; and S-100 β, 15%.
Results
❚Table 1❚ and ❚Table 2❚ show the values for S-100 β, MMP-9, BNP, and D dimer obtained with the Biosite Triage stroke panel on 30 marathon runner samples before and after the marathon along with the calculated stroke index. Mean values for MMP-9, D dimer, and BNP increased after the marathon, whereas the level for S-100 β decreased. There were statistically significant increases for MMP-9 (P < .001) and D dimer (P < .001) between premarathon and postmarathon values. The observed changes in S-100 β and BNP were not statistically significant. In addition, the premarathon and postmarathon values for the stroke marker index increased from 0.97 (normal) to 3.5 (low risk or more), which was statistically significant (P < .001). Two runners after the race (runners 10 and 21) had elevated stroke index values (6.1 and 6.9) that were higher than the cutoff of 5.9 suggested by Biosite as indicating a high risk for stroke. The premarathon and postmarathon sodium values did not differ, and none of the runners had significant hyponatremia (Table 2) .
❚Table 3❚ shows the values for troponin T before and after the marathon. Before the race, only 1 runner had a measurable level of TnT (0.014 ng/mL), whereas after the race, 21 (70%) exhibited measurable troponin values. The mean values for troponin-T increased from less than 0.01 to 0.03 ng/mL (P < .0001; 2-tailed t test; values of <0.01 were scored as 0.01 for purposes of calculating statistical significance). After the marathon, with a cutoff value of 0.05 ng/mL, 7 runners (23%) had values higher than the manufacturer's recommended cutoff for myocardial damage. In our institution, a TnT cutoff of less than 0.10 ng/mL is used. When this cutoff value is applied, none of the runners had levels more than the cutoff level, although 1 runner had a value of 0.098 ng/mL. TnT values after the race correlated only loosely with the stroke marker index value ❚Figure 1❚. However, both runners with elevated stroke index values (runners 10 and 21) also had elevated TnT values of 0.063 and 0.084 ng/mL, respectively.
Discussion
In this study of 30 asymptomatic nonelite runners following the Boston Marathon, we found that concentrations of cardiac-specific TnT rose in the great majority of subjects with a similar concomitant change in components of a novel biomarker panel suggested to be useful for the detection or exclusion of stroke.
Many laboratory test results have been reported to be abnormal in trained and recreational athletes following competition. [1] [2] [3] [4] Prolonged strenuous exercise such as marathon running may trigger acute myocardial infarction and sudden cardiac death. 9,10 Some authors have stated that there is a 6-fold increase in the absolute incidence of exercise-related sudden cardiac death in middle-aged men compared with younger men. 11 In contrast, other authors have cited no evidence of cardiac injury in marathon runners when they measured cardiac markers that include CK, CK-MB, and cardiac troponin I. 12 A number of studies have documented elevations in cardiac markers (including troponins and BNP or its amino-terminal cleavage equivalent, NT-proBNP) and in inflammatory and hemostatic markers (D dimer, CRP, and von Willebrand factor). [1] [2] [3] [4] Given their rich abundance in skeletal muscle and owing to the expected muscle injury related to prolonged running, elevations in myoglobin, CK, and the isoenzyme CK-MB more likely reflect acute skeletal muscle injury due to exertional rhabdomyolysis 5 with a cardiac signal somewhat obscured. However, elevations in cardiac-specific troponins I and T cannot be explained by skeletal muscle injury. Conventional wisdom maintains that an elevation in blood levels of cardiac troponins reflects acute myocardial injury indicative of myocardial stunning or minor myocardial damage. 3, 5 Whether elevation of troponins results from subclinical ischemia or other pathophysiologic mechanisms of myocardial injury is not clear. In our study, 70% of runners had a measurable level of troponin T after the race, and 23% had levels higher than the manufacturer's recommended cutoff 
BNP, B-type natriuretic peptide; MMP-9, matrix metalloproteinase-9. * Data are given as mean ± SD unless otherwise indicated. P values are for 2-tailed paired Student t tests. The stroke index range is 0 to 10 with 2 cutoffs: 1.3, low risk and 5.9, high risk for stroke.
value. These results provide strong evidence of subclinical myocardial injury in middle-aged marathon runners. The consequences of this injury in terms of short-or long-term risks of subsequent cardiac events are not clear. Small elevations in BNP or NT-proBNP also have been reported following competition, which may reflect subtle degrees of left ventricular dysfunction or a physiologic stimulus for natriuresis following volume overload. We also report results of a new plasma biochemical stroke panel in middle-aged nonprofessional athletes before and after the Boston Marathon. The stroke panel consists of 4 biomarkers, S-100 β, D dimer, BNP, and MMP-9. From the results for various analytes, a software algorithm calculates a stroke index ranging from 1 to 10 with 2 cutoffs: 1.3 or less, low risk; and 5.9 or more, high risk. In terms of individual markers, we observed statistically significant increases in MMP-9 and D dimer levels following competition and no significant change in S-100 β or BNP levels. The calculated stroke index increased from a mean of 0.97 to 3.5 (P < .001), and 2 subjects had index values above the high-risk cutoff value. We have no clinical or radiologic follow-up data to document the presence or absence of stroke in any of these subjects. However, it is noteworthy that in both subjects with a high-risk stroke index, the TnT values also were elevated higher than the manufacturer's recommended cutoff value (0.063 and 0.084 ng/mL). None of the subjects demonstrated overt signs of neurologic compromise, and none had symptomatic severe hyponatremia, which would be expected to put them at risk for cerebral edema. 6 The significance of the increase in stroke index following competition is not clear; given the concomitant increases in troponin in this population, the stroke index results cannot be discounted automatically as merely biochemical changes observed in a unique set of subjects using a test in an application for which it was not intended. It is necessary to point out that with the exception of MMP-9, all of the individual stroke panel markers have been reported for athletes in the literature. For example, Siegel et al 2, 3 observed elevations in the levels of D dimer, von Willebrand factor, CRP, and BNP in runners following marathon running, and elevation of the level of S-100 β, a marker of glial activation and ischemic neuronal injury, also has been reported. 13 S-100 β also is found in nonneuronal tissues such as skeletal muscle and, therefore, does not provide prima facie evidence of central nervous system injury. We observed no change in S-100 β levels following competition. Levels of MMP-9, a marker of inflammation, have not been reported for athletes following competition.
Coincident with the elevation in the D dimer level in our subjects, blood samples from the same runners recently were shown to exhibit markers of in vivo platelet activation as measured by assessment of platelet granularity and platelet clumping on the ADVIA 2120 hematology analyzer (Bayer Diagnostics, Tarrytown, NY). 14 Regardless of the presence or absence of central nervous system injury in our subjects, an elevation in MMP-9 based on a systemic inflammatory reaction to exertional rhabdomyolysis would not be unexpected. Therefore, when each stroke marker is evaluated individually, our results can be explained based on previous reports of biochemical changes in athletes due to established nonneuronal pathophysiologic mechanisms. The elevation in stroke index may represent a confluence of biochemical anomalies that does not indicate the presence of an acute cerebrovascular event. For this reason, we believe that further study is warranted, including a larger number of subjects and clinical and radiologic follow-up to determine the significance of elevated stroke indices. We report significant elevations in the levels of cardiac TnT, D dimer, MMP-9, and a multimarker stroke index in nonprofessional middle-aged marathon runners before and after competition. The changes in troponin values in 70% of our subjects most likely reflect myocardial stunning and/or true ischemic cell injury. The significance of the elevations in the stroke index and 2 of its component markers is not resolved and needs further clarification.
